SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. Hodrea J, Saeed A, Molnar A, Fintha A, et al. PLoS One 2022;17:e0263285.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hodrea J, Saeed A, Molnar A, Fintha A, et al. SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PLoS One 2022;17:e0263285.
PMID: 35176041